

Appl. No. 09/832,510
Amdt. dated March 29, 2004
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group 1642

PATENT

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-6 (Canceled).

7. (Previously presented) A method for detecting a nucleic acid in a biological sample, wherein the nucleic acid encodes a peptide capable of specifically binding to a Lym-1 antibody, the method comprising the following steps, in the following order:

(a) contacting the sample with an oligonucleotide primer pair capable of amplifying a subsequence of an MHC nucleic acid, which subsequence encodes a polypeptide having a sequence comprising R₁ - R₂ - R₃ - R₄ - R₅ - R₆ - R₇ - R₈ - R₉ - R₁₀ - R₁₁ - R₁₂ - R₁₃ - R₁₄ - R₁₅ - R₁₆, wherein R₁ is Gln, Lys, or Arg; R₂ is Arg; R₃ and R₄ are members independently selected from the group consisting of all amino acids; R₅ is Ala, Glu, Asp, Val, Leu or Ile; R₆ and R₇ are members independently selected from the group consisting of all amino acids; R₈ is Thr; R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, and R₁₅ are members independently selected from the group consisting of all amino acids; and, R₁₆ is Val (SEQ ID NO:2),

(b) amplifying the nucleic acid; and

(c) detecting the amplified nucleic acid.

8. (Previously presented) The method of claim 7, wherein the MHC nucleic acid is HLA-DR 10.

9. (Previously presented) The method of claim 7, wherein the subsequence encodes a peptide wherein R₁ is Gln, Lys, or Arg; R₂ is Arg; R₃ is Arg; R₄ is Ala; R₅ is Ala; R₆ is Val; R₇ is Asp; R₈ is Thr; R₉ is Tyr; R₁₀ is Cys; R₁₁ is Arg; R₁₂ is His; R₁₃ is Asn; R₁₄ is Tyr; R₁₅ is Gly, and R₁₆ is Val (SEQ ID NO:2).

Appl. No. 09/832,510
Amdt. dated March 29, 2004
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group 1642

PATENT

10. (Original) The method of claim 7, wherein the biological sample comprises a B cell.
11. (Original) The method of claim 10, wherein the B cell is a B lymphocytic non-Hodgkin's lymphoma cell.
12. (Original) The method of claim 11, wherein the non-Hodgkin's lymphoma cell is selected from the group consisting of a B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CCL/SLL) cell, a lymphoplasmacytoid lymphoma (LPL) cell, a follicular lymphoma (FL) cell, a mucosa-associated lymphoid tissue lymphoma (MALTL) cell, a splenic lymphoma with villous lymphocytes (SLVL) cell and a mantle cell lymphoma cell.
13. (Original) The method of claim 7, wherein the biological sample is a body fluid sample or a biopsy sample.
14. (Original) The method of claim 13, wherein the body fluid sample is a blood sample.
- 15-34. (Canceled)
35. (Previously presented) A method for detecting a nucleic acid in a biological sample, wherein the nucleic acid encodes a peptide capable of specifically binding to a Lym-1 antibody; the method comprising the following steps, performed in the following order:
(a) contacting the sample with an oligonucleotide primer pair capable of amplifying a subsequence of an MHC nucleic acid, which subsequence encodes a polypeptide having a sequence consisting essentially of R₁ - R₂ - R₃ - R₄ - R₅ - R₆ - R₇ - R₈ - R₉ - R₁₀ - R₁₁ - R₁₂ - R₁₃ - R₁₄ - R₁₅ - R₁₆, wherein R₁ is Gln, Lys, or Arg; R₂ is Arg; R₃ and R₄ are members independently selected from the group consisting of all amino acids; R₅ is Ala, Glu,

Appl. No. 09/832,510
Amdt. dated March 29, 2004
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group 1642

PATENT

Asp, Val, Leu or Ile; R₆ and R₇ are members independently selected from the group consisting of all amino acids; R₈ is Thr; R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, and R₁₅ are members independently selected from the group consisting of all amino acids; and, R₁₆ is Val (SEQ ID NO:2).

- (b) amplifying the nucleic acid; and
- (c) detecting the amplified nucleic acid.

36. (Previously presented) A method of claim 35, wherein the MHC nucleic acid is HLA-DR 10.

37. (Previously presented) The method of claim 35, wherein the subsequence encodes a peptide wherein R₁ is Gln, Lys, or Arg; R₂ is Arg; R₃ is Arg; R₄ is Ala; R₅ is Ala; R₆ is Val; R₇ is Asp; R₈ is Thr; R₉ is Tyr; R₁₀ is Cys; R₁₁ is Arg; R₁₂ is His; R₁₃ is Asn; R₁₄ is Tyr; R₁₅ is Gly, and R₁₆ is Val (SEQ ID NO:2).

38. (Previously presented) The method of claim 35, wherein the biological sample comprises a B cell.

39. (Previously presented) The method of claim 38, wherein the B cell is a B lymphocytic non-Hodgkin's lymphoma cell.

40. (Previously presented) The method of claim 39, wherein the non-Hodgkin's lymphoma cell is selected from the group consisting of a B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CCL/SLL) cell, a lymphoplasmacytoid lymphoma (LPL) cell, a follicular lymphoma (FL) cell, a mucosa-associated lymphoid tissue lymphoma (MALTL) cell, a splenic lymphoma with villous lymphocytes (SLVL) cell and a mantle cell lymphoma cell.

Appl. No. 09/832,510
Amdt. dated March 29, 2004
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group 1642

PATENT

41. (Previously presented) The method of claim 35, wherein the biological sample is a body fluid sample or a biopsy sample.

42 (Previously presented) The method of claim 41, wherein the body fluid sample is a blood sample.

43-45. (Canceled)